Navigation Links
DURATION-6 Top-Line Study Results Announced
Date:3/3/2011

mes. Actual results could differ materially from those discussed or implied in this press release due to a number of risks and uncertainties, including the risk that BYDUREON may not be approved by the FDA and/or the European Commission as soon as anticipated or at all; the companies' response to the FDA's complete response letter may not be submitted in a timely manner and/or the information provided in such response may not satisfy the FDA; the FDA may request additional information prior to approval; BYETTA and/or the approval of BYDUREON and future revenues from BYDUREON, if approved, and/or BYETTA (exenatide for injection) may be affected by competition; unexpected new data; safety and technical issues; clinical trials, including the clinical trial mentioned in this press release, not being completed in a timely manner, not confirming previous results, not being predictive of real world use or not achieving the intended clinical endpoints; label expansion requests or NDA filings not receiving regulatory approval; the commercial launch of BYDUREON being delayed; or manufacturing and supply issues. The potential for BYETTA and/or BYDUREON may also be affected by government and commercial reimbursement and pricing decisions, the pace of market acceptance, or scientific, regulatory and other issues and risks inherent in the development and commercialization of pharmaceutical products including those inherent in the collaboration with and dependence upon Amylin, Lilly and/or Alkermes. These and additional risks and uncertainties are described more fully in Amylin's, Lilly's and Alkermes' most recent SEC filings including their Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K. Amylin, Lilly and Alkermes undertake no duty to update these forward-looking statements.

BYDUREON™ and BYETTA® are trademarks of Amylin Pharmaceuticals, Inc., and Medisorb® is a registered trademark of Alkerme
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.; Eli Lilly and Company; Alkermes, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. CuraGen Announces Top-Line Phase II Results on Velafermin
2. Top-Line Efficacy Data Presented from Phase 2 Trial of Alemtuzumab in Multiple Sclerosis
3. Exelixis Reports Top-Line Results of the Phase 2 Trial of XL784 in Patients With Proteinuria Associated With Diabetic Nephropathy
4. Schering-Plough Reports Top-Line Results of the IDEAL Study
5. InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update
6. Statement From the Lupus Foundation of America Regarding the Release of Top-Line Results From a Study of Rituxan for the Treatment of Lupus
7. Cardica Reports Positive Top-Line Results and Submits 510(k) for PAS-Port(R) Proximal Anastomosis System in Cardiac Bypass Surgery
8. Inspires Phase 3 CF Trial, Using PARIs Nebulizer & Compressor, Shows Positive Top-Line Results
9. Medivation to Host Conference Call at 5 p.m. EDT Monday to Discuss Top-Line Phase 2 Study Results in Huntingtons Disease
10. Medivation Announces Positive Top-Line Results From Phase 2 Dimebon Study in Huntingtons Disease
11. NicOx Announces Top-Line Results From Naproxcinod 52-Week 301 Safety Extension
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... 2014  Soligenix, Inc. (OTCQB: SNGX) (Soligenix or ... that address unmet medical needs in the areas ... agreement has been reached with the US Food ... a pivotal, Phase 3 clinical trial evaluating its ... cutaneous T-cell lymphoma (CTCL).  SGX301 ...
(Date:9/17/2014)... China , Sept. 17, 2014 Mindray ... been officially released worldwide. The system has been showcased ... Barcelona during 14-17th September, and is scheduled ... Designed to be the most efficient workhorse ... versatile diagnostic tools with a perfectly optimized user experience ...
(Date:9/16/2014)... , 17 settembre 2014 Hologic, ... oggi il lancio in Europa del Tomcat, un ... è una piattaforma multifunzionale completamente automatizzata, progettata per ... inefficienze ed i rischi di errore legati alla ... dello strumento Tomcat di Hologic riduce il carico ...
Breaking Medicine Technology:Soligenix Announces FDA Clearance of Phase 3 Clinical Protocol of SGX301 in Cutaneous T-Cell Lymphoma 2Soligenix Announces FDA Clearance of Phase 3 Clinical Protocol of SGX301 in Cutaneous T-Cell Lymphoma 3Soligenix Announces FDA Clearance of Phase 3 Clinical Protocol of SGX301 in Cutaneous T-Cell Lymphoma 4Soligenix Announces FDA Clearance of Phase 3 Clinical Protocol of SGX301 in Cutaneous T-Cell Lymphoma 5Soligenix Announces FDA Clearance of Phase 3 Clinical Protocol of SGX301 in Cutaneous T-Cell Lymphoma 6Soligenix Announces FDA Clearance of Phase 3 Clinical Protocol of SGX301 in Cutaneous T-Cell Lymphoma 7Quality Exams at Your Fingertips 2Hologic annuncia il lancio dello strumento preanalitico Tomcat in Europa 2Hologic annuncia il lancio dello strumento preanalitico Tomcat in Europa 3
... Janam Technologies LLC, a leading ... communicate wirelessly, today announced a new mobile healthcare ... product line with antimicrobial versions of the XM66 and ... provide the healthcare sector with rugged antimicrobial devices ...
... SILVER SPRING, Md., Oct. 14 The U.S. ... that their over-the-counter (OTC) chelation products are unapproved ... violation of federal law to make unproven claims ... chelation products. (Logo:   http://photos.prnewswire.com/prnh/20090824/FDALOGO ) ...
Cached Medicine Technology:Janam Introduces Mobile Healthcare Product Line 2FDA Issues Warnings to Marketers of Unapproved 'Chelation' Products 2FDA Issues Warnings to Marketers of Unapproved 'Chelation' Products 3FDA Issues Warnings to Marketers of Unapproved 'Chelation' Products 4
(Date:9/17/2014)... Kathleen Doheny HealthDay Reporter ... major food and beverage companies have made good on their ... report finds. The companies, acting together through the Healthy ... the market between 2007 and 2012 and 1.5 trillion by ... "The 16 companies collectively met their pledge and exceeded their ...
(Date:9/17/2014)... at Moffitt Cancer Center, including Center Director Thomas A. Sellers, ... discovered 23 new regions of the genome that influence the ... Sept. 14 in Nature Genetics . , Prostate cancer ... 1 in 6 men will be diagnosed with the disease ... A man with one close relative, a brother or father ...
(Date:9/17/2014)... facial paralysis are perceived as being less happy simply ... facial expression, a new study from an Oregon State ... the important role the face plays in everyday communication ... with facial paralysis because of their disability, said Kathleen ... of Liberal Arts at Oregon State University. , "People ...
(Date:9/17/2014)... 2014 Tools4ever, the market ... solutions and Boston Software Systems, leader in ... relationship. Under the agreement, Tools4ever will ... functionality within its identity and password management ... healthcare automation platforms that streamline complex processes ...
(Date:9/17/2014)... Kessler Foundation is the recipient of one of ... Multiple Sclerosis (MS) Alliance. Nancy Chiaravalloti, PhD, ... Research, is principal investigator of the study, which ... in individuals with progressive multiple sclerosis. The Foundation ... the Alliance to investigators in nine countries, with ...
Breaking Medicine News(10 mins):Health News:Major U.S. Food Makers Cut 6.4 Trillion Calories From Products: Report 2Health News:Major U.S. Food Makers Cut 6.4 Trillion Calories From Products: Report 3Health News:Lack of facial expression leads to perceptions of unhappiness, new OSU research shows 2Health News:Lack of facial expression leads to perceptions of unhappiness, new OSU research shows 3Health News:Tools4ever Partners with Boston Software Systems to Automate Identity and Password Management 2Health News:Tools4ever Partners with Boston Software Systems to Automate Identity and Password Management 3Health News:Tools4ever Partners with Boston Software Systems to Automate Identity and Password Management 4Health News:Kessler Foundation receives first-round grant from International Progressive Multiple Sclerosis Alliance 2
... Older workers benefit most from a modest health behavior ... personal coaching. University of Illinois at Chicago researchers ... interventions assessing older workers, health behaviors and outcomes. The ... an upcoming issue of the American Journal of Public ...
... April 14 (HealthDay News) -- Trying to make the best of ... cope with losing their jobs, a new United Kingdom study finds. ... with their job loss were able to see the event as ... volunteering and study. They also took a contemplative view of ...
... SEATTLE Everyone knows that eating a low-fat, low-calorie diet ... study led by researchers at Fred Hutchinson Cancer Research Center ... body fat, diet and exercise are most effective when done ... of this randomized trial, led by Anne McTiernan, M.D., Ph.D., ...
... 14, 2011 An enzyme essential for DNA replication and ... exploited as anti-cancer therapy, say researchers at The Scripps Research ... in the April 15, 2011 issue of the journal Cell, ... flap endonucleases, which are essential to the life of a ...
... of Alberta shows that for best results in stable patients ... is the key to the best outcomes. Study co-authors Mark ... Clark, researcher in the Faculty of Nursing, along with fellow ... Public Health, and Ian Paterson in the Faculty of Medicine ...
... During the winter of 2008�, a three-week armed conflict ... named "Operation Cast Lead" resulted in hundreds of rocket ... this time children and their families spent hours and ... Although the psychological effects of children,s health are ...
Cached Medicine News:Health News:Older workers benefit from high-tech, high-touch health promotion 2Health News:Good Attitude Critical When Coping With Layoff Trauma 2Health News:Study finds diet plus exercise is more effective for weight loss than either method alone 2Health News:Study finds diet plus exercise is more effective for weight loss than either method alone 3Health News:Study suggests enzyme crucial to DNA replication may provide potent anti-cancer drug target 2Health News:Study suggests enzyme crucial to DNA replication may provide potent anti-cancer drug target 3Health News:Study suggests enzyme crucial to DNA replication may provide potent anti-cancer drug target 4Health News:Heart needs work after heart attack: U of A Study challenges the notion that the heart must rest 2Health News:Teachers-based intervention provides stress resistance in war-exposed children 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: